Table 1.
MUC1-based clinical trials
| Cancer type | Biological | Composition and targets | Study phase | Trial number | Status | Year | Enrollment |
|---|---|---|---|---|---|---|---|
| Bladder cancer | PANVAC | CEA-MUC1-TRICOM | II | NCT02015104 | Completed | 2013 | 32 |
| CV301 | CEA, MUC1, ICAM-1, LFA-3, and B7-1 | II | NCT03628716 | Halted | 2018 | 43 | |
| Dendritic cells | MUC1 | II | NCT04184232 | Completed | 2019 | 17 | |
| Renal cell carcinoma | Vaccine | MUC1, CEA, Her2/neu, telomerase, survivin, MAGE-A1 | I/II | Completed | 2003 | 30 | |
| TG4010 | MUC1-IL2 | II | Completed | 2003 | 37 | ||
| Antibody | Anti-CD3-MUC1 | II | NCT03540199 | Withdrawn | 2018 | 0 | |
| Dendritic cells | MUC1-PADRE | I/II | Completed | 2020 | 20 | ||
| CAR-T cells | P-MUC1C-ALLO1 | I | NCT05239143 | Recruiting | 2022 | 100 | |
| Prostate cancer | Vaccine | VV/MUC-1/IL-2 | I | Completed | 1998 | 22 | |
| Vaccine | MUC1-KLH | I | NCT00005632 | Completed | 1999 | 27 | |
| TG4010 | MUC1-IL2 | II | NCT00040170 | Terminated | 2002 | 40 | |
| Vaccine | MUC1 | I | NCT00374049 | Completed | 2006 | 14 | |
| Dendritic cells | Tn-MUC1 | I/II | NCT00852007 | Completed | 2009 | 20 | |
| L-BLP25 | MUC1 | II | NCT01496131 | Completed | 2011 | 28 | |
| CV9104 | PSA, PSMA, PSCA, STEAP, PAP, and MUC1 | I/II | NCT01817738 | Terminated | 2012 | 197 | |
| Vaccine | Ad-sig-hMUC1/ecdCD40L | I | NCT02140996 | Unknown | 2014 | 24 | |
| CV9104 | PSA, PSMA, PSCA, STEAP, PAP, and MUC1 | II | NCT02140138 | Terminated | 2014 | 35 | |
| Dendritic cells | NY-ESO-1, MAGE-C2, and MUC1 | II | NCT02692976 | Completed | 2015 | 21 | |
| Vaccine | Ad5 CEA/MUC1/Brachyury | I | NCT03384316 | Completed | 2018 | 11 | |
| Vaccine | Ad5 PSA/MUC1/brachyury | I | NCT03481816 | Completed | 2018 | 18 |